157 related articles for article (PubMed ID: 19643596)
1. TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis.
Chen B; Liu S; Wang XL; Xu W; Li Y; Zhao WH; Wu JQ
Eur J Cancer; 2009 Sep; 45(14):2598-605. PubMed ID: 19643596
[TBL] [Abstract][Full Text] [Related]
2. Association of DR4 (TRAIL-R1) polymorphisms with cancer risk in Caucasians: an updated meta-analysis.
Chen W; Tang WR; Zhang M; Chang K; Wei YL
Asian Pac J Cancer Prev; 2014; 15(6):2889-92. PubMed ID: 24761920
[TBL] [Abstract][Full Text] [Related]
3. Association of four polymorphisms in the death receptor 4 gene with cancer risk: an updated meta-analysis.
Lu J; Qin Q; Zhan LL; Liu J; Zhu HC; Zhang C; Xu LP; Liu ZM; Yang X; Cheng HY; Sun XC
Tumour Biol; 2014 Jun; 35(6):5149-58. PubMed ID: 24492941
[TBL] [Abstract][Full Text] [Related]
4. Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma.
Zayed SA; Zahran NM; Khorshied MM; Abdel-Aziz AO; Mahmoud O; Morsy SA; Shousha HI; Elbaz TM; Nabeel MM; Harb ARK
J Med Virol; 2019 Aug; 91(8):1537-1544. PubMed ID: 30945308
[TBL] [Abstract][Full Text] [Related]
5. Genetic variations in tumor ecrosis factor related apoptosis-inducing ligand receptor-1 (TRAIL-R1) gene and the susceptibility to b-cell non-hodgkin lymphoma (B-NHL) in Egypt.
Khorshied M; Soliman N; Khorshid O; Bakr S
Cancer Biomark; 2021; 32(4):451-458. PubMed ID: 34275891
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of trail receptor 1 (DR4) polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma.
Alsalawy NF; Darwish RK; Kamal MM; ElTaweel AE; Shousha HI; Elbaz TM
J Med Virol; 2018 Mar; 90(3):490-496. PubMed ID: 28975649
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in the tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) do not contribute but Death Receptor (DR4) genes may contribute to susceptibility to head and neck cancer in Pakistani population.
Sarwar R; Mansoor Q; Farooqi AA; Shahzad S; Fayyaz S; Ismail M
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):53-6. PubMed ID: 26718429
[TBL] [Abstract][Full Text] [Related]
8. TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.
Körner C; Riesner K; Krämer B; Eisenhardt M; Glässner A; Wolter F; Berg T; Müller T; Sauerbruch T; Nattermann J; Spengler U; Nischalke HD
BMC Cancer; 2012 Mar; 12():85. PubMed ID: 22401174
[TBL] [Abstract][Full Text] [Related]
9. There is no significant association between death receptor 4 (DR4) gene polymorphisms and lung cancer in Turkish population.
Taştemir-Korkmaz D; Demirhan O; Kuleci S; Hastürk S
Pathol Oncol Res; 2013 Oct; 19(4):779-84. PubMed ID: 23661154
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4) genes contribute to susceptibility to colorectal cancer in pakistani population.
Zahoor A; Mansoor Q; Farooqi AA; Fayyaz S; Naz G; Ismail M
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):108-12. PubMed ID: 26518902
[TBL] [Abstract][Full Text] [Related]
11. Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels.
Verim A; Turan S; Farooqi AA; Kahraman OT; Tepe-Karaca C; Yildiz Y; Naiboglu B; Ozkan NE; Ergen A; Isitmangil GA; Yaylim I
Asian Pac J Cancer Prev; 2014; 15(24):10697-703. PubMed ID: 25605161
[TBL] [Abstract][Full Text] [Related]
12. Meta-Analysis of the Association Between FAS Ligand and TRAIL Genetic Polymorphisms and Intervertebral Disc Degeneration Susceptibility in Chinese Han population.
Huang X; Zhang W; Shao Z
Spine (Phila Pa 1976); 2018 Nov; 43(22):1602-1608. PubMed ID: 29652777
[TBL] [Abstract][Full Text] [Related]
13. The Impact of TRAIL (C1595T and G1525A) and DR4 (rs20576) Gene Polymorphisms on Systemic Lupus Erythematosus.
Sandoughi M; Salimi S; Shahraki-Ghadimi H; Saravani M
Biochem Genet; 2020 Aug; 58(4):649-659. PubMed ID: 32342239
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand and death receptor genes contribute to susceptibility to bladder cancer.
Timirci-Kahraman O; Ozkan NE; Turan S; Farooqi AA; Verim L; Ozturk T; Inal-Gultekin G; Isbir T; Ozturk O; Yaylim I
Genet Test Mol Biomarkers; 2015 Jun; 19(6):309-15. PubMed ID: 25955868
[TBL] [Abstract][Full Text] [Related]
15. Genetic association between TRAIL-R1 Thr209Arg and cancer susceptibility.
Geng P; Li J; Wang N; Liao Y; Ou J; Sa R; Xie G; Liu C; Li H; Xiang L; Liang H
Sci Rep; 2015 Aug; 5():10382. PubMed ID: 26315998
[TBL] [Abstract][Full Text] [Related]
16. Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population.
Rai R; Sharma KL; Sharma S; Misra S; Kumar A; Mittal B
PLoS One; 2014; 9(2):e90264. PubMed ID: 24587306
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of caspase 9 polymorphisms in promoter and exon sequence on cancer susceptibility.
Xu W; Jiang S; Xu Y; Chen B; Li Y; Zong F; Zhao W; Wu J
PLoS One; 2012; 7(5):e37443. PubMed ID: 22616010
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of DNA methyltransferase 3B 149 C>T and risk of colorectal cancer: a meta-analysis.
Meng Q; Zhang J; Lian B; Song C
Tumour Biol; 2014 Mar; 35(3):2367-72. PubMed ID: 24178910
[TBL] [Abstract][Full Text] [Related]
19. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.
Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J
Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838
[TBL] [Abstract][Full Text] [Related]
20. Association of TNF-α promoter-308 A/G polymorphism with susceptibility to systemic lupus erythematosus: a meta-analysis.
Pan HF; Leng RX; Wang C; Qin WZ; Chen LL; Zha ZQ; Tao JH; Ye DQ
Rheumatol Int; 2012 Jul; 32(7):2083-92. PubMed ID: 21499693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
